Virtu Financial LLC Raises Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Virtu Financial LLC grew its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 372.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 23,294 shares of the medical research company's stock after buying an additional 18,365 shares during the quarter. Virtu Financial LLC's holdings in Amgen were worth $6,071,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of AMGN. Swedbank AB grew its position in shares of Amgen by 1.1% during the 3rd quarter. Swedbank AB now owns 538,899 shares of the medical research company's stock valued at $173,639,000 after acquiring an additional 5,751 shares during the period. Quest Partners LLC grew its holdings in Amgen by 1,568.7% during the third quarter. Quest Partners LLC now owns 1,919 shares of the medical research company's stock valued at $618,000 after purchasing an additional 1,804 shares during the period. Citizens Financial Group Inc. RI increased its position in Amgen by 4.4% in the third quarter. Citizens Financial Group Inc. RI now owns 14,844 shares of the medical research company's stock worth $4,783,000 after buying an additional 626 shares during the last quarter. LPL Financial LLC raised its stake in shares of Amgen by 0.7% in the third quarter. LPL Financial LLC now owns 751,945 shares of the medical research company's stock valued at $242,284,000 after buying an additional 4,999 shares during the period. Finally, Thompson Siegel & Walmsley LLC lifted its position in shares of Amgen by 7.4% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 41,548 shares of the medical research company's stock valued at $13,387,000 after buying an additional 2,871 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

Remove Ads

Amgen Price Performance

NASDAQ:AMGN traded down $1.15 during midday trading on Wednesday, hitting $305.71. The company had a trading volume of 2,374,942 shares, compared to its average volume of 2,548,828. The company has a market capitalization of $164.23 billion, a PE ratio of 40.49, a P/E/G ratio of 2.63 and a beta of 0.53. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The stock's fifty day moving average price is $298.92 and its 200-day moving average price is $298.41.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be paid a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.11%. The ex-dividend date of this dividend is Friday, May 16th. Amgen's dividend payout ratio (DPR) is presently 126.09%.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the transaction, the senior vice president now owns 7,210 shares in the company, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP David M. Reese sold 25,225 shares of the business's stock in a transaction on Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the sale, the executive vice president now directly owns 36,922 shares of the company's stock, valued at $11,240,533.68. This represents a 40.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,341 shares of company stock worth $20,644,335. 0.69% of the stock is currently owned by insiders.

Analyst Ratings Changes

AMGN has been the topic of several research reports. Leerink Partners lowered their price target on shares of Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Truist Financial dropped their target price on Amgen from $333.00 to $298.00 and set a "hold" rating on the stock in a research report on Wednesday, January 8th. Citigroup reiterated a "neutral" rating on shares of Amgen in a research report on Wednesday, February 5th. Finally, Piper Sandler Companies reissued an "overweight" rating and set a $310.00 price objective on shares of Amgen in a report on Thursday, January 2nd. Two analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $314.04.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.